《上市公司章程指引》及《江苏康为 江苏康为世纪生物科技股份有限公司 世纪生物科技股份有限公司章程》（以下简称"《公司章程》"）的规 定，结合公司实际情况，制定本制度。 第一章 总则 董事提出辞任的，公司应当在 60 日内完成补选，确保董事会及其专 门委员会构成符合法律法规和公司章程的规定。 第八条 公司董事、高级管理人员为自然人，有下列情形之一的，不能担任 公司的董事或高级管理人员： 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员的辞任、 任期届满、解任以及其他导致董事、高级管理人员实际离职等情形。 第二章 离职情形与生效条件 第三条 公司董事辞任应当提交书面辞职报告。董事辞任的，自公司收到通 知之日生效，公司将在两个交易日内披露有关情况。 第四条 如存在以下情形的，在改选出的董事就任前，原董事仍应当依照法 律、行政法规、部门规章和《公司章程》规定，履行董事职务，但 存在相关法规另有规定的除外： (一) 董事任期届满未及时改选，或者董事在任期内辞任导致董事 会成员低于法定最低人数； (二) 审计委员会成员辞任导致审计委员会成员低于法定最低人数， 或者欠缺担任召集人的会计专业人士； (三) 独立董 ...

Core Points - The article outlines the regulations and responsibilities of the Audit Committee of Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the need for independent directors and their qualifications [2][4][5] - The Audit Committee is responsible for overseeing financial reporting, internal controls, and external audits, ensuring compliance with relevant laws and regulations [3][6][7] Group 1: Audit Committee Structure - The Audit Committee must consist of directors who are not senior management, with a majority being independent directors [2][4] - Independent directors must have relevant professional knowledge and experience to effectively supervise and evaluate audit work [2][4] - The committee is responsible for proposing the hiring or replacement of external auditors and reviewing their fees and terms [5][6] Group 2: Responsibilities and Authority - The main responsibilities of the Audit Committee include supervising external audits, evaluating internal audits, and reviewing financial information [6][7] - The committee must ensure the accuracy and completeness of financial reports and address any significant issues related to fraud or misrepresentation [6][7] - The committee has the authority to hire independent consultants and legal advisors as needed [10][12] Group 3: Meeting Procedures - The Audit Committee is required to hold at least one regular meeting each quarter and can convene additional meetings as necessary [10][12] - A quorum for meetings requires the presence of at least two-thirds of the committee members [10][12] - Meeting records must be kept for a minimum of ten years, detailing attendance, agenda, and decisions made [11][13]

Core Viewpoint - Wuxi Xiangsheng Medical Technology Co., Ltd. is actively implementing a "Quality Improvement and Efficiency Enhancement" action plan to enhance investor returns and strengthen its core competitiveness through continuous innovation and talent development [1][2]. Group 1: Innovation and R&D - The company has maintained a research and development (R&D) personnel ratio of 34.3%, with 178 R&D staff, averaging over 10 years of experience, contributing to sustained innovation [1]. - As of the reporting period, the company holds 391 authorized patents, including 158 invention patents and 99 software copyrights, demonstrating its strong R&D capabilities [2]. - The company has accelerated its international product registration process, obtaining 43 new foreign market access licenses during the reporting period, thereby expanding its overseas market share [2]. Group 2: Commercialization and Market Presence - The company showcased its full range of products and AI-assisted diagnostic solutions at over 70 global industry events, enhancing brand exposure and clinical value [2]. - The "SonoGlobal 2025" agent conference and the "Evergreen Elite Project" were launched to upgrade core partners' capabilities from product sales to solution delivery, establishing a sustainable strategic cooperation system [2]. Group 3: Investor Communication and Disclosure - The company has established a comprehensive information disclosure management system to fulfill its obligations and has actively communicated with investors through various channels [3][4]. - Regular performance briefings and visual presentations of reports have been implemented to enhance investor understanding of the company's operations [4]. Group 4: Investor Returns - Since its listing in 2019, the company has maintained an average dividend payout ratio exceeding 65%, with a total dividend distribution of RMB 464 million [5]. - For the 2024 fiscal year, the company plans to distribute cash dividends of RMB 10 per 10 shares, totaling RMB 112 million, which represents 79.62% of the net profit attributable to shareholders [5]. Group 5: Corporate Governance - The company emphasizes the importance of a sound governance structure and effective internal control systems to enhance operational compliance and decision-making [6]. - The company has organized training for key personnel to ensure compliance with regulations and improve understanding of market dynamics [6].

股票代码：600258 股票简称：首旅酒店 编号：临 2025-035 北京首旅酒店（集团）股份有限公司 第九届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京首旅酒店（集团）股份有限公司（以下简称"公司"或"首旅酒店"） 第九届董事会第十一次会议于 2025 年 8 月 27 日（星期三）上午 9：30 以通讯方 式召开。本次会议的通知已于 8 月 17 日以邮件方式送达公司各位董事、监事和 公司高管人员。本次会议应到董事 11 名，11 名董事亲自出席会议。符合《公司 法》和《公司章程》的有关规定。会议提出并经过表决通过以下议案： 一、以赞成 11 票，占全体董事表决票数的 100%；回避 0 票；反对 0 票；弃 权 0 票的表决结果通过了《公司 2025 年半年度报告全文及摘要》。 《公司 2025 年半年度报告》已经 2025 年 8 月 20 日下午 16 时召开的董事会 审计委员会会议事前审核通过，同意提交公司董事会审议。 公司 2025 年半年度报告全文刊登在上交所网站 http ...

Group 1 - The board of directors of Jiangsu Zhenjiang New Energy Equipment Co., Ltd. held its 12th meeting of the 4th session on August 27, 2025, with all directors present and all resolutions passed unanimously without opposition [1][2]. - The company plans to amend its Articles of Association, Shareholders' Meeting Rules, and Board Meeting Rules to comply with the latest legal regulations, and will abolish the Supervisory Board, transferring its powers to the Audit Committee of the Board [2][3]. - All resolutions passed during the meeting received a unanimous vote of 5 in favor, with no votes against or abstentions [3][4]. Group 2 - The amendments to the governance documents will be submitted for approval at the shareholders' meeting, and upon approval, the board will authorize relevant personnel to handle the necessary business registration changes [2][3]. - The company aims to enhance its governance level and ensure compliance with regulatory requirements through these amendments [2][4].

Group 1 - The company announced a change in registered capital and amendments to its Articles of Association, which will be submitted for shareholder approval [1][4] - As of August 27, 2025, the company’s registered capital increased by 10,479.00 CNY due to the conversion of "Haoyuan Convertible Bonds" into 10,479 shares [1] - The company completed the registration procedures for the first vesting period of the 2022 restricted stock incentive plan, resulting in an increase of 648,570 shares and registered capital by 648,570.00 CNY [2] - The company reduced its total share capital by 47,725 shares and registered capital by 47,725.00 CNY due to the cancellation of compensation shares related to performance commitments [3] - The company completed the registration for the second vesting period of the 2023 restricted stock incentive plan, increasing total share capital by 527,660 shares and registered capital by 527,660.00 CNY [4] - The total share capital changed from 210,959,781 shares to 212,098,765 shares, and registered capital changed from 210,959,781.00 CNY to 212,098,765.00 CNY [4] Group 2 - The company plans to amend its Articles of Association to reflect changes in registered capital and total share capital, in accordance with relevant laws and regulations [4] - The specific amendments to the Articles of Association include updates to the registered capital and total share capital clauses [4]

Core Points - The company held its third supervisory board meeting on August 28, 2025, where all three attending supervisors approved the agenda items [1][2] - The supervisory board approved the 2025 semi-annual report, confirming its compliance with relevant laws and regulations, and ensuring the report's accuracy and completeness [2][3] - The board also approved a special report on the use of raised funds, affirming its adherence to regulatory requirements [3] - A significant decision was made to abolish the supervisory board and amend the company's articles of association, transferring the supervisory functions to the audit committee of the board [3][4] - The proposed changes to the articles of association will require approval at the company's first extraordinary general meeting in 2025 [4][5] - The company is revising its governance systems in line with the new Company Law effective from July 1, 2024, to enhance operational standards and governance structure [5][6]

无锡祥生医疗科技股份有限公司 董事会提名委员会工作细则 第一章 总则 第二章 人员组成 第四章 会议的召开与通知 第十六条 提名委员会可根据需要召开会议。 提名委员会主任或二名以上委员联名可要求召开提名委员会会议。 第十七条 提名委员会会议主要对公司董事、总经理及其他高级管理人员上一年 度的工作表现及是否存在需要更换董事、总经理及其他高级管理人员 的情形进行讨论和审议。 第一条 为完善无锡祥生医疗科技股份有限公司(以下简称"公司")法人治理 结构, 增强董事会选举程序的科学性、民主性, 优化董事会的组成人 员结构, 公司特设立董事会提名委员会(以下简称"提名委员会")。 第二条 为使提名委员会规范、高效地开展工作, 公司董事会根据《中华人民 共和国公司法》(以下简称"《公司法》") 、《上市公司独立董事管 理办法》等有关法律、法规和规范性文件及《无锡祥生医疗科技股份 有限公司章程》(以下简称"《公司章程》")的有关规定, 制定本工作 细则。 第三条 提名委员会是董事会按照股东会决议设立的专门工作机构, 主要负责 向公司董事会提出更换、推荐新任董事候选人及高级管理人员候选人 的意见或建议, 对董事会负责。 第四 ...

Group 1 - The company has established an Audit Committee under the Board of Directors to enhance decision-making and ensure effective supervision of the management team [1][4] - The Audit Committee consists of three directors, with at least two being independent directors, and is chaired by an independent director with accounting expertise [2][5] - The Audit Committee is responsible for reviewing financial information, supervising internal and external audits, and ensuring the establishment of effective internal controls [4][6] Group 2 - The Audit Committee must have a majority of its members present to exercise its powers, and it is required to hold at least one meeting each quarter [11][23] - The committee is tasked with evaluating the company's internal control systems and must report on its findings alongside the annual financial report [7][9] - The Audit Committee is also responsible for hiring and supervising external auditors, ensuring their independence and adherence to professional standards [10][13] Group 3 - The committee must disclose its annual performance and activities on the Shanghai Stock Exchange website alongside the company's annual report [4][6] - In case of any irregularities, the Audit Committee is obligated to prompt the Board to take necessary actions and disclose relevant information [7][10] - The committee's decisions require a majority vote from all members, and any conflicts of interest must be disclosed and managed appropriately [42][49]

在委员人数达到规定人数三人以前, 薪酬与考核委员会暂停行使本 工作细则规定的职权。 第十条 《公司法》《公司章程》关于董事义务的规定适用于薪酬与考核委 员会委员。 第三章 职责权限 董事会对薪酬与考核委员会的建议未采纳或者未完全采纳的, 应当 在董事会决议中记载薪酬与考核委员会的意见及未采纳的具体理由, 并进行披露。 第一条 为建立健全无锡祥生医疗科技股份有限公司(以下简称"公司")董事 (非独立董事)及高级管理人员的考核和薪酬管理制度, 完善公司治 理结构, 公司特设立董事会薪酬与考核委员会(以下简称"薪酬与考 核委员会")。 第二条 为使薪酬与考核委员会规范、高效地开展工作, 公司董事会根据《中 华人民共和国公司法》(以下简称"《公司法》") 、《上市公司独 立董事管理办法》等有关法律、法规和规范性文件以及《无锡祥生 医疗科技股份有限公司章程》(以下简称"《公司章程》")的有关规 定, 制定本工作细则。 第三条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构, 主要负责制定公司董事及高级管理人员的考核标准并进行考核; 负 责制定、审查公司董事及高级管理人员的薪酬政策与方案, 对董事会 负责。 第 ...